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Protein–ligand complex neocarzinostatin (NCS) is a small,
thermostable protein-ligand complex that is able to deliver
its ligand cargo into live mammalian cells where it induces
DNA damage. Apo-NCS is able to functionally display
complementarity determining regions loops, and has been
hypothesised to act as a cell-penetrating protein, which
would make it an ideal scaffold for cell targeting, and
subsequent intracellular delivery of small-molecule drugs.
In order to evaluate apo-NCS as a cell penetrating protein,
we have evaluated the efficiency of its internalisation into
live HeLa cells using matrix-assisted laser-desorption ion-
ization-time-of-flight mass spectrometry and fluorescence
microscopy. Following incubation of cells with apo-NCS,
we observed no evidence of internalisation.
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delivery/Neocarzinostatin/protein–drug conjugate
Introduction
The extensively studied neocarzinostatin (NCS) complex pro-
duced by Streptomyces carzinostaticus is a 12-kDa protein
(Kuromizu et al., 1986) bound to an enediyne chromophore
ligand (Napier et al., 1979). The enediyne chromophore is
toxic (Kappen et al., 1980), which has been attributed to
binding of the chromophore to DNA, upon which it induces
double-stranded DNA cleavage (D’Andrea and Haseltine,
1978; Hensens et al., 1994). The SMANCS construct, in
which NCS is conjugated to poly(styrene comaleic acid)
(Maeda et al., 1979; Oda and Maeda, 1987) has been used
clinically to treat hepatomas in humans (Konno, 1992;
Konno et al., 1994).
The NMR (Takashima et al., 2005; Caddick et al., 2006)
and crystal (Kim et al., 1993; Teplyakov et al., 1993) struc-
tures of NCS have been elucidated, which reveal a hydropho-
bic groove that binds the chromophore with nanomolar
affinity (Povirk and Goldberg, 1980). The considerable stabil-
ity of apo-NCS to reduction and denaturation (Meienhofer
et al., 1972; Sudhahar and Chin, 2006), and its ability to bind
a wide range of synthetic ligands have stimulated efforts to
develop ligands for NCS for use as chemotherapeutics
(Caddick et al., 2006). Such an activity could be coupled
with the ability of NCS to functionally display complemen-
tarity determining regions loops from antibodies (Nicaise
et al., 2004).
Analyses of DNA replication rates (Kappen et al., 1980)
and gene transcription (Schaus et al., 2001) following incu-
bation of live cells with holo-NCS suggest that holo-NCS is
able to induce chromosomal DNA damage, and hence that
the chromophore is able to enter the nucleus. The chromo-
phore is highly unstable in its ‘free’ form, and so it has been
suggested that the chromophore is protected from degrad-
ation in the cytoplasm by the NCS protein (Kappen et al.,
1980). In addition, microscopy of live cells treated with fluor-
escently labelled holo-NCS suggests that holo-NCS is able to
internalise, and accumulate in the nucleus (Takeshita et al.,
1980; Oda and Maeda, 1987).
Given the favourable biochemical properties of apo-NCS,
and the strong evidence for internalisation of holo-NCS, we
have investigated the possibility that recombinant apo-NCS
could act as a cell-penetrating protein, and therefore provide
a platform for the targeted intracellular delivery of therapeut-
ic cargo.
Here, we evaluate apo-NCS internalisation into live mamma-
lian cells using two complementary techniques. Biotinylated-
and rhodamine-labelled conjugates of two distinct cysteine
mutants of apo-NCS were generated. Following incubation of
HeLa cells with the relevant conjugate, matrix-assisted laser-
desorption ionization-time-of-flight (MALDI-TOF) mass spec-
trometry allowed quantitative analysis of intact apo-NCS
whereas fluorescence microscopy allowed detection of
apo-NCS that may be intact or proteolytically degraded.
Methods
Protein expression
NCS(wild-type) was subcloned from the vector p-CANTAB
into pNIC28-Bsa4 using the primers TACTTCCAATCC
ATGCTACAGGGAGCTGCTCCAACC and TATCCACCTT
TACTGCTAGTTGAAGGAGATAGCAAC. NCS(þC) con-
struct was generated by subcloning into pNIC28-Bsa4 using
the primers TACTTCCAATCCATGCTACAGGGAGCTGCT
CCAACC and TATCCACCTTTACTGTCAGCAACCACCA
CCAGAGTTGAAGGAGATAGCAACGCC. The NCS(S14C)
construct was generated by site-directed mutagenesis using the
primers CATAAGCTGGAATACAATTTTAACTGCCACAAT
GTTTACATCACCGCC and GGCGGTGATGTAAACATTG
TGGCAGTTAAAATTGTATTCCAGCTTATG.
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Non-isotopically labelled proteins were expressed in SHuffle
cells (New England Biolabs) using the manufacturer’s protocol.
15N–NCS(þC) was expressed in Shuffle cells in isotopic
media, namely M9 salts with glucose (20 mM), 15N-ammonium
chloride (0.1%), CaCl2 (100 mM), MgSO4 (2 mM) and Basal
Medium Eagle vitamins (Sigma-Aldrich). All proteins were
purified by nickel chromatography in the presence of
b-mercaptoethanol (14 mM). The His6 tag was removed by
incubation with tobacco etch virus (TEV) protease for 2 h at
308C, and apo-NCS was repurified by size-exclusion chroma-
tography in water, using a HiPrep 26/60 sephacryl S-100
column. All subsequent modifications were completed at
48C. Purified apo-NCS (150 mM) was reduced using tris(2-
carboxyethyl)phosphine (TCEP, 200 mM) in sodium phos-
phate (50 mM, pH 8).
MALDI-TOF mass spectrometry
All mass spectra were generated following addition of the
sample to a saturated solution of sinapinic acid in CH3CN :
H2O : CF3COOH (50 : 50 : 0.1). Each samples of 2 1 ml
were deposited and analysed using a Bruker Microflex Mass
Spectrometer in positive linear ion mode. Spectra were accu-
mulated over several hundred laser shots.
Protein conjugation
Reduced apo-NCS (1 mg/ml) was labelled with biotin by in-
cubation with EZ-Link Maleimide-PEG2-biotin (Pierce,
500 mM) from a stock of EZ-Link Maleimide-PEG2-biotin in
water for 1 h. Excess labelling reagent was removed by diafiltra-
tion and the products were characterised by MALDI-TOF MS.
Reduced apo-NCS was labelled with tetramethylrhoda-
mine (TMR) by incubation with of TMR-5(6)C2-maleimide
(TMR-Mal, AnaSpec, 500 mM) from a stock of 20 mM
TMR-5(6)C2-maleimide in dimethylformamide for 1 h.
NCS-TMR was fully separated from free TMR-Mal by
size-exclusion chromatography, using a HiPrep 26/60 sepha-
cryl S-100 column in water. Products were characterised by
MALDI-TOF MS.
Circular dichroism
Circular dichroism (CD) spectra were recorded in 1-mm
fused silica cuvettes using a Jasco J-715 spectrophotometer
at room temperature in water, with 0.1 mg/ml of each con-
struct. Thermal unfolding curves were obtained by monitor-
ing the CD signal at 211 nm using 2-mm pathlength cuvettes
and a heating rate of 18/min.
Generation of Tat-TMR
Tat-Cys (sequence H-RKKRRQRRRGC-NH2, C S Bio,
500 mmol) was solubilised in degassed sodium phosphate
(100 mM, pH8, 1 ml). Tat-Cys was reduced by addition of
TCEP (500 mmol) and labeled by with TMR-5(6)C2-
maleimide (1.5 mM), from a stock of 20 mM TMR-5(6)C2-
maleimide in dimethylfomamide, for 1 h on ice. The product
was concentrated by freeze-drying, followed by solubilisation
in a minimum volume of 0.1% trifluoroacetic acid. The
product was purified by high-performance liquid chromatog-
raphy using a Vydac C18 (218TP) column, and freeze-dried.
The product was characterised by MALDI-TOF MS.
Quantification of internalisation by MALDI mass
spectrometry
HeLa cells were seeded in sterile conditions in 24-well plates
for 12 h before internalisation experiments. Sub-confluent
cells (106 cells/well) were incubated for 1 h with
NCS(S14C/þC)biotin (10 mM) in Hanks media. Cells were
washed three times with Hanks media (1 ml), then treated
for 5 min at 378C with pronase (0.5 mg/ml, 200 ml) in
sodium phosphate buffer (100 mM, pH 7.4). The digestion
was halted by an addition of 100 ml 2 COmplete Mini
Protease Inhibitors with EDTA (Roche) with BSA (0.1 mg/ml),
and transferred to an eppendorf on ice. The cells were
washed with of Tris-HCl buffer (50 mM, pH 7.4, 500 ml),
and then with buffer A (1 ml of Tris-HCl buffer (50 mM, pH
7.4) containing 0.1% BSA); the cells were recovered at each
stage by centrifugation for 2 min at 640 g. The pellet was
resuspended in lysis solution (0.3% Triton X-100, 1 M NaCl,
150 ml) and the internal standard was added (0, 10 or
20 pmol 15N-NCS(þC)-biotin). The mixture was heated for
15 min at 1008C and then centrifuged for 5 min at 7080 g.
The supernatant was mixed with of buffer A (850 ml) and
incubated for 1 h with streptavidin-coated magnetic beads
(Dynabeads M-280, Invitrogen, 10 ml). Subsequently, the
beads were washed with buffer A (2  200 ml), buffer A
containing 0.1% sodium dodecyl sulphate (2  200 ml),
buffer A containing 1 M NaCl (2  200 ml), H20 (3 
200 ml), biotin (10 mM, 50 ml), H20 (50 ml). Protein was
eluted from the beads by incubation within a matrix of a
saturated solution of sinapinic acid in CH3CN : H2O :
CF3COOH (50 : 50 : 0.1; 3 ml) for 10 min at room tempera-
ture, then analysed by MALDI-TOF MS. Internalisation
experiments were performed in triplicate and repeated at
least twice independently.
For experiments without protease digestion, the cells were
incubated and washed three times with Hanks media (1 ml),
as described above. Lysis solution with internal standard
(300 ml) was added, and the 24-well plate was placed in a
boiling water bath for 15 min. The solution was then centri-
fuged and mixed with of buffer A (1700 ml) and incubated
for 1 h with streptavidin-coated magnetic beads (10 ml). The
beads were then treated as described above.
Fluorescence microscopy
Concentrated NCS(S14C)-TMR, NCS(þC)-TMR or Tat-
TMR were diluted to 10 mM concentration in Hanks media
(Sigma-Aldrich). Adherent HeLa cells were incubated for 1 h
at 378C with the peptide or protein, followed by washing
three times with Hanks media. Cells were then immediately
imaged on a Deltavision fluorescence microscope using an
Olympus 100X/1.40, Plan Apo objective, 0.035s exposure
time with 10% transmission. z-sections were taken through
the entire depth of the cells, and the images were decon-
volved. An average intensity projection was generated, and
brightness and contrast were adjusted equivalently for all
images. At least 10 cells were observed in each condition,
and 5 cells were imaged for each.
Results and discussion
Apo-NCS contains four native cysteines that form two stable
disulfide bonds, which are resistant to the commonly used
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thiol-reducing agents (Meienhofer et al., 1972). We hence
reasoned that by a using a point mutation strategy, we could
introduce free cysteine residues into the NCS sequence that
would allow facile and site-selective conjugation of either
biotin or fluorophore labels. Apo-NCS was cloned into
pNIC28-Bsa4, which introduces an N-terminal His6 tag that
can be cleaved by TEV protease. Two mutants with a single
free cysteine were generated, namely NCS(S14C) (Ser to
Cys mutation on loop 1, near the N-terminus), and
NCS(þC) (addition of SGGGC at the C terminus) (see
Supplementary data). These constructs were expressed in
Escherichia coli and the His6 tag was removed by TEV pro-
tease. Both constructs were reduced using TCEP, and fluores-
cently labelled with tetramethylrhodamine-maleimide to
generate NCS(S14C)-TMR and NCS(þC)-TMR, or biotiny-
lated with biotin-maleimide to generate NCS(S14C)-biotin
and NCS(þC)-biotin.
CD spectra were obtained for each of the modified
apo-NCS constructs described in this paper (Fig. 1). These
spectra are consistent with previously published CD spectra
for apo-NCS (Jayachithra et al., 2005; Sudhahar and Chin,
2006), Thermal denaturation (Fig. 2) confirms that the Tm of
the constructs are all between 61 and 668C, and fully revers-
ible. We hence conclude that apo-NCS remains stably folded
at 378C following introduction of a fifth cysteine residue,
treatment with TCEP and introduction of biotin or tetra-
methylrhodamine. Analysis of these constructs by mass spec-
trometry confirmed the addition of either a fluorophore or
biotin per protein molecule (see Supplementary data).
In order to determine how efficiently apo-NCS is interna-
lised into mammalian cells, we adapted a strategy (Burlina
et al., 2006) that has been used previously for quantifying
the internalisation of small cell-penetrating peptides (CPPs).
The method allows quantification of the amount of interna-
lised CPP by adding a known amount of isotopically labelled
CPP as an internal standard prior to analysis. The desorption/
ionisation properties of the CPP and the isotopically labelled
CPP are identical, which allows quantification and simultan-
eous detection by MALDI-TOF mass spectrometry. In this
study, isotopically labelled 15N-NCS(þC)-biotin was pre-
pared to quantify NCS cellular uptake (see Supplementary
data). The mass spectrum shown in Fig. 3 is a 1 : 1 mixture
Fig. 1. CD spectra of unlabelled NCS(WT) and labelled NCS constructs.
Fig. 2. Thermal denaturation curves of unlabelled NCS(WT) and labelled
NCS constructs, monitored by CD.
Fig. 3. MALDI-TOF mass spectrum of 1 : 1 14N-NCS(þC)-biotin and
15N-NCS(þC)-biotin (10 pmol of each protein were mixed, then pulled
down using streptavidin-coated magnetic beads).
Fig. 4. MALDI-TOF mass spectrum of internalised NCS(þC)-biotin. [Cells
were incubated with 14N-NCS(þC)-biotin (10 mM, 1 h at 378C), then
pronase (0.5 mg/ml, 200 ml). 15N-NCS(þC)-biotin (10 pmol) was added
before lysis and pulldown of biotinylated species.]
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of 14N-NCS(þC)-biotin and 15N-NCS(þC)-biotin. Partial
hydrolysis of the maleimide (mass þ18 Da), a known phe-
nomenon under alkaline conditions,[22] was observed for the
15N-NCS(þC)-biotin construct. However, partial maleimide
hydrolysis does not change the desorption/ionisation effi-
ciency of the compound, as the peak area ratio is 1 : 1.
HeLa cells were first incubated with 14N-NCS(þC)-biotin.
Conditions were employed that have previously been shown
to permit internalisation of holo-NCS (Oda and Maeda,
1987). Cells incubated at 378C are known to permit cell
entry by endocytosis, pinocytosis, and direct translocation
(Zorko and Langel, 2005). Mass spectra were obtained fol-
lowing the addition of internal standard (15N-NCS(þC)-
biotin) and subsequent to cell lysis. The internal standard
was detected clearly on the mass spectrum, but no signal cor-
responding to intact 14N-NCS(þC)-biotin was observed
(Fig. 4). No NCS intracellular digest was observed either but
it should be noted that small biotinylated digests (m/z ,
1000) would be difficult to detect. This experiment suggested
that apo-NCS was not internalised inside cells, but internal-
isation followed by rapid degradation could not be excluded.
To evaluate whether C-terminal biotinylation was inherently
detrimental for cellular uptake, the experiment was repeated
with apo-NCS mutant NCS(S14C)-biotin, biotinylated near
the N-terminus. In order to minimise potential signal suppres-
sion effects, no internal standard was added. Again, no inter-
nalised apo-NCS was detected (see Supplementary data).
To detect any membrane-bound apo-NCS in addition to
any internalised apo–NCS, the procedure was repeated, such
that after incubation with 14N-NCS(þC)-biotin, the cells
were lysed without pronase treatment. This eliminates any
degradation of membrane-bound NCS by proteases. A small
peak was observed at the expected mass for 14N-NCS(þC)
biotin (Fig. 5). This peak is too small to quantify accurately,
and may be background noise. Given the sensitivity of NCS
detection by this technique, this suggests that less than
2 pmol apo-NCS is cell-associated following washing. The
combined data suggest that apo-NCS neither tightly binds to
nor internalises into HeLa cells.
We could not exclude from these experiments a rapid deg-
radation of the internalised apo-NCS preventing its detection
by MALDI-TOF MS (vide supra). To test this hypothesis,
live HeLa cells were incubated with either fluorescently-
labelled NCS(S14C)-TMR or NCS(þC)-TMR. The inter-
nalisation efficiency of NCS was compared with that of
trans-activating transcriptional activator (Tat) from human
immunodeficiency virus 1 (Vive`s et al., 1997), a peptide that
is known to internalise relatively weakly compared with
other CPPs, with an estimated intracellular concentration of
1 mM when incubated under similar conditions used in this
experiment with CHO cells (Burlina et al., 2005). As
expected, Tat was internalised. In contrast, incubation with
NCS(S14C)-TMR and NCS(þC)-TMR did not result in fluor-
escently labelled cells (Fig. 6) confirming that NCS does not
enter cells. Using longer exposure images with higher illumin-
ation intensities (data not shown), it was clear that cells
Fig. 5. MALDI-TOF mass spectrum of cell-associated NCS(þC)-biotin.
[Cells were incubated with 14N-NCS(þC)-biotin (10 mM, 1 h, 378C).
15N-NCS(þC)-biotin was added before lysis and pulldown of biotinylated
species.]
Fig. 6. Microscopy of HeLa cells treated with tetramethylrhodamine-labelled NCS (scale bars are 5 mm).
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incubated with NCS(S14C)-TMR or NCS(þC)-TMR were
often less fluorescent than the surrounding media.
These results clearly demonstrate that apo-NCS does not
internalise into mammalian cells. Given that there is strong
evidence for internalisation of holo-NCS, these results suggest
that binding of the chromophore might be required for efficient
internalisation to occur. This could be explained by a conform-
ational change in the protein upon chromophore binding.
A conformational change between the previously reported
NMR structures of holo-NCS (1O5P) (Takashima et al., 2005)
and apo-NCS (1j5H) (Urbaniak et al., 2002) is consistent with
this hypothesis. The study on the effect of both natural and
non-natural ligand binding on the internalisation of NCS into
mammalian cells is on-going in our laboratory.
Supplementary data
Supplementary data are available at PEDS online.
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